• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SMARCA4 缺陷型未分化子宫肉瘤的病理特征和免疫微环境。

Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma.

机构信息

Department of Pathology, Xiamen Humanity Hospital Fujian Medical University, No.3777 Xianyue Street, Xiamen, Fujian, 361000, China.

Department of Pathology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

出版信息

Diagn Pathol. 2023 May 16;18(1):62. doi: 10.1186/s13000-023-01347-3.

DOI:10.1186/s13000-023-01347-3
PMID:37194064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10186742/
Abstract

SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) is a highly invasive single-gene malignant tumor caused by mutations in the SMARCA4 gene. SDUS has a poor prognosis, with no established treatment strategy at present. Further, there is a lack of relevant research on the role of the immune microenvironment in SDUS worldwide. Here, we report a case of SDUS that was diagnosed and analysed using morphological, immunohistochemical, and molecular detection techniques, along with the analysis of the immune microenvironment. By immunohistochemistry, the tumor cells showed retained INI-1 expression, focal CD10 expression, and loss of BRG1, CK-pan, synaptophysin, desmin, and ER expression. Further, some of the immune cells expressing CD3 and CD8 had infiltrated into the SDUS, but no PD-L1 expression was detected. The multiple immunofluorescent staining results showed that a proportion of the immune cells and SDUS cells expressed CD8/CD68/PD-1/PD-L1. Therefore, our report will help in the diagnostic awareness of SDUS.

摘要

SMARCA4 缺陷型未分化子宫肉瘤(SDUS)是一种由 SMARCA4 基因突变引起的高度侵袭性单基因恶性肿瘤。SDUS 预后不良,目前尚无既定的治疗策略。此外,全球范围内对 SDUS 免疫微环境的作用缺乏相关研究。在这里,我们报告了一例 SDUS 的病例,该病例通过形态学、免疫组织化学和分子检测技术进行了诊断和分析,并对免疫微环境进行了分析。免疫组织化学显示,肿瘤细胞保留 INI-1 表达,局灶性 CD10 表达,BRG1、CK-泛、突触素、结蛋白和 ER 表达缺失。此外,一些表达 CD3 和 CD8 的免疫细胞浸润到 SDUS 中,但未检测到 PD-L1 表达。多重免疫荧光染色结果显示,一部分免疫细胞和 SDUS 细胞表达 CD8/CD68/PD-1/PD-L1。因此,我们的报告将有助于提高对 SDUS 的诊断意识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/234f6fec3b58/13000_2023_1347_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/527e58b0f0c8/13000_2023_1347_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/ff8a1bc6546a/13000_2023_1347_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/8e1adc099126/13000_2023_1347_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/43ab97645a05/13000_2023_1347_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/234f6fec3b58/13000_2023_1347_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/527e58b0f0c8/13000_2023_1347_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/ff8a1bc6546a/13000_2023_1347_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/8e1adc099126/13000_2023_1347_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/43ab97645a05/13000_2023_1347_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31cb/10186742/234f6fec3b58/13000_2023_1347_Fig5_HTML.jpg

相似文献

1
Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma.SMARCA4 缺陷型未分化子宫肉瘤的病理特征和免疫微环境。
Diagn Pathol. 2023 May 16;18(1):62. doi: 10.1186/s13000-023-01347-3.
2
SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities.SMARCA4 缺陷型子宫肉瘤和未分化子宫内膜癌是两种不同的临床病理实体。
Am J Surg Pathol. 2020 Feb;44(2):263-270. doi: 10.1097/PAS.0000000000001375.
3
The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.SOX2 在鉴别诊断 SMARCA4(BRG1)缺陷型子宫肿瘤中的价值。
Hum Pathol. 2022 Jun;124:45-55. doi: 10.1016/j.humpath.2022.03.009. Epub 2022 Mar 22.
4
The Potential of Immunotherapy for SMARCA4-Deficient Undifferentiated Uterine Sarcoma (SDUS).免疫疗法治疗 SMARCA4 缺陷型未分化子宫肉瘤(SDUS)的潜力。
Biomolecules. 2024 Aug 11;14(8):987. doi: 10.3390/biom14080987.
5
SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.SMARCA4 缺陷性胸壁肉瘤:一种具有未分化横纹肌样形态和侵袭性行为的独特临床病理实体。
Mod Pathol. 2017 Oct;30(10):1422-1432. doi: 10.1038/modpathol.2017.61. Epub 2017 Jun 23.
6
-deficient Undifferentiated Uterine Sarcoma: Clinicopathological Features of an Emerging Entity.- 缺乏特定特征的未分化子宫肉瘤:一种新出现实体的临床病理特征
Int J Surg Pathol. 2023 Feb;31(1):104-109. doi: 10.1177/10668969221095266. Epub 2022 Apr 24.
7
Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.子宫间质肿瘤中 SMARCA4、SMARCA2 和 SMARCB1 表达缺失不常见。
Hum Pathol. 2021 Oct;116:12-21. doi: 10.1016/j.humpath.2021.07.001. Epub 2021 Jul 13.
8
SMARCA4 / BRG1 -deficient Uterine Neoplasm With Hybrid Adenosarcoma and Carcinoma Features: Expanding the Molecular-morphologic Spectrum of SMARCA4 -driven Gynecologic Malignancies.具有混合性腺肉瘤和癌特征的SMARCA4/BRG1缺陷型子宫肿瘤:拓展SMARCA4驱动的妇科恶性肿瘤的分子形态学谱
Int J Gynecol Pathol. 2024 Jul 1;43(4):354-361. doi: 10.1097/PGP.0000000000000996. Epub 2023 Dec 12.
9
SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.SMARCA4 失活定义了具有横纹肌样和小细胞特征以及种系突变关联的未分化子宫肉瘤亚群。
Mod Pathol. 2019 Nov;32(11):1675-1687. doi: 10.1038/s41379-019-0303-z. Epub 2019 Jun 12.
10
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.SMARCA4 缺陷型未分化子宫肉瘤(子宫恶性横纹肌样瘤):一种与未分化癌不同的临床病理实体。
Mod Pathol. 2018 Sep;31(9):1442-1456. doi: 10.1038/s41379-018-0049-z. Epub 2018 Apr 26.

引用本文的文献

1
Molecular Insights in Endometrial Stromal Sarcomas: Exploring New Targets for Novel Therapeutic Approaches.子宫内膜间质肉瘤的分子见解:探索新型治疗方法的新靶点
Biomolecules. 2025 Feb 11;15(2):265. doi: 10.3390/biom15020265.
2
Undifferentiated endometrial carcinoma diagnosed during perimenopausal hormone therapy: a case report and literature review.围绝经期激素治疗期间诊断出的未分化子宫内膜癌:一例病例报告及文献综述
Front Oncol. 2024 Nov 22;14:1440246. doi: 10.3389/fonc.2024.1440246. eCollection 2024.
3
Undifferentiated uterine sarcoma : experience of a single center.

本文引用的文献

1
SMARCA4-deficient uterine sarcoma: A case report and a concise review.SMARCA4缺陷型子宫肉瘤:一例病例报告及简要综述。
Case Rep Womens Health. 2020 Jun 3;27:e00231. doi: 10.1016/j.crwh.2020.e00231. eCollection 2020 Jul.
2
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines.卵巢小细胞癌,嗜血钙型——遗传学、新的治疗靶点和当前的管理指南。
Clin Cancer Res. 2020 Aug 1;26(15):3908-3917. doi: 10.1158/1078-0432.CCR-19-3797. Epub 2020 Mar 10.
3
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
未分化子宫肉瘤:单中心经验
World J Surg Oncol. 2024 Dec 5;22(1):325. doi: 10.1186/s12957-024-03610-3.
4
SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors.年轻女性中SMARCA4缺陷型子宫肿瘤:对免疫检查点抑制剂的反应
Int Cancer Conf J. 2024 Sep 17;13(4):515-519. doi: 10.1007/s13691-024-00721-2. eCollection 2024 Oct.
5
SMARCA4‑deficient uterine adnexal tumor with ascites: A case report and literature review.伴有腹水的SMARCA4缺陷型子宫附件肿瘤:一例报告及文献复习
Oncol Lett. 2024 Jun 5;28(2):357. doi: 10.3892/ol.2024.14490. eCollection 2024 Aug.
6
Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.哺乳动物 SWI/SNF 复合物亚基基因的突变对免疫肿瘤微环境的影响。
Cancer Genomics Proteomics. 2024 Jan-Feb;21(1):88-101. doi: 10.21873/cgp.20432.
胚系 SMARCA4 突变在卵巢小细胞癌、高钙血症型和 SMARCA4 缺陷型未分化子宫肉瘤中的作用:一个家族的临床特征及与大样本队列的比较。
Gynecol Oncol. 2020 Apr;157(1):106-114. doi: 10.1016/j.ygyno.2019.10.031. Epub 2020 Jan 15.
4
Uterine mesenchymal tumours: recent advances.子宫间质肿瘤:最新进展。
Histopathology. 2020 Jan;76(1):64-75. doi: 10.1111/his.14008.
5
SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities.SMARCA4 缺陷型子宫肉瘤和未分化子宫内膜癌是两种不同的临床病理实体。
Am J Surg Pathol. 2020 Feb;44(2):263-270. doi: 10.1097/PAS.0000000000001375.
6
SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.SMARCA4 失活定义了具有横纹肌样和小细胞特征以及种系突变关联的未分化子宫肉瘤亚群。
Mod Pathol. 2019 Nov;32(11):1675-1687. doi: 10.1038/s41379-019-0303-z. Epub 2019 Jun 12.
7
The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.哺乳动物 SWI/SNF 家族复合物的 ATP 酶模块介导亚基复合物身份和与催化活性无关的基因组靶向。
Nat Genet. 2019 Apr;51(4):618-626. doi: 10.1038/s41588-019-0363-5. Epub 2019 Mar 11.
8
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.SMARCA4 缺陷型未分化子宫肉瘤(子宫恶性横纹肌样瘤):一种与未分化癌不同的临床病理实体。
Mod Pathol. 2018 Sep;31(9):1442-1456. doi: 10.1038/s41379-018-0049-z. Epub 2018 Apr 26.
9
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.卵巢小细胞癌伴高钙血症的免疫激活微环境:免疫检查点阻断的理由。
J Natl Cancer Inst. 2018 Jul 1;110(7):787-790. doi: 10.1093/jnci/djx277.
10
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: and Preclinical Models.通过抑制EZH2选择性杀伤SMARCA2和SMARCA4缺陷型高钙血症型卵巢小细胞癌细胞及临床前模型
Mol Cancer Ther. 2017 May;16(5):850-860. doi: 10.1158/1535-7163.MCT-16-0678. Epub 2017 Mar 14.